MiMedx Group (MDXG) Projected to Announce Quarterly Earnings on Wednesday

Key Points

• MiMedx Group is expected to report Q3 2026 results after the market closes on October 28, with analysts forecasting earnings of $0.0003 per share and revenue of $68.56 million.
• In its prior quarter, MiMedx reported a $0.05-per-share loss, in line with estimates, while revenue of $64.36 million exceeded expectations of $63.46 million.
• The stock recently traded at $4.23, down 3.4%, while analysts maintain a consensus “Moderate Buy” rating and an average price target of $8.57.

MiMedx Group (NASDAQ:MDXG - Get Free Report) is expected to be releasing its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect MiMedx Group to announce earnings of $0.0003 per share and revenue of $68.56 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 4:30 PM ET.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). The company had revenue of $64.36 million during the quarter, compared to analysts' expectations of $63.46 million. MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%. On average, analysts expect MiMedx Group to post ($0.10) EPS for the current fiscal year and $0.17 EPS for the next fiscal year.

MiMedx Group Trading Down 3.4%

MDXG opened at $4.23 on Wednesday. The firm has a 50 day simple moving average of $4.56 and a 200 day simple moving average of $4.09. MiMedx Group has a fifty-two week low of $3.03 and a fifty-two week high of $7.97. The company has a market cap of $616.56 million, a price-to-earnings ratio of 105.78 and a beta of 1.18. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.33 and a quick ratio of 4.79.

Wall Street Analysts Forecast Growth

A number of research firms have commented on MDXG. Raymond James Financial set a $8.00 target price on shares of MiMedx Group in a report on Monday, August 17th. Cantor Fitzgerald reiterated an "overweight" rating on shares of MiMedx Group in a research report on Tuesday, September 15th. Craig Hallum increased their price target on MiMedx Group from $6.00 to $8.00 and gave the company a "buy" rating in a research note on Thursday, August 27th. Wall Street Zen upgraded MiMedx Group from a "sell" rating to a "hold" rating in a research report on Saturday, August 29th. Finally, Seaport Research Partners lowered MiMedx Group to a "neutral" rating in a research report on Monday, August 17th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $8.57.

MiMedx Group Company Profile

MiMedx Group, Inc is a regenerative healthcare company that develops, manufactures and markets human placental tissue allografts and related biomaterial products. Its products are derived from donated human placental tissue and are processed for use in healthcare settings, including wound care, surgery and orthopedic applications.

The company's portfolio includes tissue allografts such as EPIFIX, EPIEFFECT, GRAFIX and AMNIOFIX. These products are designed to support the management of chronic and acute wounds, surgical reconstruction and other clinical procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.